Friday Foghorn from ipkitten.blogspot.com Attention! I have big news!
UK IPO invites bids by early September for research into the IP valuation market. Are you brimming full of ideas about the IP valuation market? If so, prick up your ...
Share via E–mail | Twitter | Facebook
Fed Cir Finds § 101 Patent Eligible Subject Matter in BASCOM from dunlapcodding.com Jeremy McKinney
On June 27, 2016, a three judge panel of the Federal Circuit delivered a decision in BASCOM Global Internet v. AT&T; Mobility LLC. The court held that while BASCOM’s asserted claims ...
Share via E–mail | Twitter | Facebook
USPTO Initiates Post-Prosecution Pilot Program from www.patentdocs.org By Donald Zuhn –- On Monday, the U.S. Patent and Trademark Office published a notice in the Federal Register (81 Fed. Reg. 44845) regarding the initiation of a new pilot program intended to enhance patent ...
Share via E–mail | Twitter | Facebook
Orphan Drugs Finding Home In Markets: Could Be 20% Of All Sales By 2020 from www.ip-watch.org Worldwide sales for orphan drugs are forecast to reach $178 billion by 2020, according to a recent industry report. Moreover, the orphan drug market is expected to grow almost 12 percent per year, a level ...
Share via E–mail | Twitter | Facebook
Patent for Remotely Accessing and Controlling an Application Over a Network Invalid Under 35 U.S.C. § 101 from docketreport.blogspot.com The special master recommended granting defendants' motions to dismiss because the asserted claims of plaintiff’s patent for remotely accessing and controlling an application over a network encompassed unpatentable subject matter and found that the ...
Share via E–mail | Twitter | Facebook
CAFC in Skyhawke continues the ordinary rule counseling against prevailing party appeals from ipbiz.blogspot.com The CAFC observed:
SkyHawke points us
to no authority to suggest that Congress intended the use
of “dissatisfied with” in conjunction with “final decision”
to broaden the appeal rights from Board decisions to
include those ... Share via E–mail | Twitter | Facebook
Orphan drug status for Crestor? from ipbiz.blogspot.com Note the article in the New York Times by Andrew Pollack about Crestor titled
AstraZeneca Pushes to Protect Crestor From Generic CompetitionNote separately the article by Murphy: Unintended Effects of Orphan Product Designation for ...
Share via E–mail | Twitter | Facebook
Venue Challenges Part 2 from patentlyo.com While law professors call for venue patent reform, the TC Heartland venue and personal jurisdiction challenge appears to still have legs. In April 2016, the Federal Circuit rejected the mandamus action, but the Supreme Court ...
Share via E–mail | Twitter | Facebook
TTIP Negotiators Need Many More Nights To Negotiate – And Are Planning Just That from www.ip-watch.org Top negotiators of the European Union and United States today underlined after the 14th round of negotiations for the Transatlantic Trade and Investment Partnership (TTIP) that they are still on track for finalising the deal ...
Share via E–mail | Twitter | Facebook